Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Liabilities and Shareholders Equity (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Liabilities and Shareholders Equity readings, the most recent being $1.0 billion for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 181.67% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 billion through Dec 2025, up 62.85% year-over-year, with the annual reading at $1.0 billion for FY2025, 181.67% up from the prior year.
  • Liabilities and Shareholders Equity hit $1.0 billion in Q4 2025 for Terns Pharmaceuticals, up from $301.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.0 billion in Q4 2025 and bottomed at $144.9 million in Q2 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $292.7 million, with a median of $270.1 million recorded in 2023.
  • The largest annual shift saw Liabilities and Shareholders Equity decreased 22.95% in 2022 before it soared 181.67% in 2025.
  • Terns Pharmaceuticals' Liabilities and Shareholders Equity stood at $168.1 million in 2021, then skyrocketed by 70.78% to $287.0 million in 2022, then fell by 6.45% to $268.5 million in 2023, then soared by 35.53% to $363.9 million in 2024, then surged by 181.67% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for TERN's Liabilities and Shareholders Equity are $1.0 billion (Q4 2025), $301.7 million (Q3 2025), and $320.4 million (Q2 2025).